Curriculum vitae for mark cushman - Purdue College of Pharmacy ...

Mark Cushman
20. $10,000, Indiana Elks, "Targeting DNA Cross-linking Agents to Specific Regions by
Conjugation to Minor Groove Binders," 1995-1996.
21. $20,400, Purdue Research Foundation, "Targeting DNA Cross-linking Agents to Specific
Regions by Conjugation to Minor Groove Binders," 1996-1997.
22. $568,592, National Institutes of Health, RO1-AI-36624, "Synthesis of New Anti-HIV
Agents Related to Cosalane," 1995-1998.
23. $574,585, National Institutes of Health, RO1-GM-51469, "Ligands for Probing the
Active Site of Lumazine Synthase," 1995-1999.
24. $1,013,191, National Institutes of Health, NO1-CM-67260, "Synthesis of Congeners and
Prodrugs," 1998-2001.
25. $23,332, Purdue Research Foundation, "Design and Synthesis of Novel Non-nucleoside
HIV-1 Reverse Transcriptase Inhibitors for the Treatment of AIDS," 1998-2000.
26. $566,395 (including cost sharing by Purdue totaling $216,000), National Institutes of
Health, 1 S10 RR12025-01A1, "High Resolution Mass Spectrometer," 1998.
27. $505,113, National Institutes of Health, RO1-AI-43637, "Synthesis of New NNRTIs for
the Treatment of AIDS," 1998-2001.
28. $50,000, Showalter Trust, "Design, Synthesis, and Biological Evaluation of Novel
Protein-tyrosine Kinase Inhibitors and Potential Anticancer Agents," 1999-2000.
29. $25,292, Cancer Center Purdue Research Foundation Research Grant, "Design and
Synthesis of Novel Protein-Tyrosine Kinase Inhibitors," 2000-2002.
30. $29,376 (total annual support) "Training in Drug and Carcinogen-DNA Interactions"
training grant 5T32-09634, NIH, 2000-2002.
31. $924,221, National Institutes of Health, RO1 GM51469, "Ligands for Probing the Active
Site of Lumazine Synthase," 2000-2004.
32. $873,170, National Institutes of Health, UO1 CA89566, "Novel Indenoisoquinoline
Topoisomerase I Inhibitors," 2001-2005.
33. $25,000, EntreMed, Inc., "Design and Synthesis of 2-Methoxyestradiol Analogs," 2002-
2003.
34. $50,000, EntreMed, Inc., "Design and Synthesis of 2-Methoxyestradiol Analogs," 2003-
2004.
35. $806,868, National Institutes of Health, AI043637, "Synthesis of New NNRTIs for the
Treatment of AIDS," 2003-2006.
36. $600,000, National Institutes of Health, 1 U54 AI57153-01, "Development of Anti-viral
Strategies for Enveloped Viruses," 2003-2008. This is part of a larger grant application,
involving 11 Midwestern universities, entitled "Bioterrorism: Molecular Analysis and
Intervention", with Richard Kuhn at the PI and Mark Cushman as a Co-PI.
37. $971,544, National Institutes of Health, RO1 GM51469, "Ligands for Probing the Active
Site of Lumazine Synthase," 2005-2009.
38. $6,845,355, National Institutes of Health, PO1 CA48112-13, "Natural Inhibitors of
Carcinogenesis," 2005-2010. This is a large program project grant with John Pezzuto as
the PI and Mark Cushman as one of the a co-PIs. The total cost for the Cushman
subproject is $987,011.
39. $1,250,472, National Institutes of Health, U01 CA89566-05, "Novel Indenoisoquinoline
Topoisomerase I Inhibitors," 2005-2010.
40. $209,614, EntreMed, "Design and Synthesis of Tubulin Polymerization Inhibitors,"
2006-2008.
44